Updated: July 2024
To apply for an opportunity listed below, submit your proposal through the RUSH Research Portal. Select “Non-Profit: Philanthropy” as the “Funding Source” when creating a new master project and grant within the portal.
If you are unsure which office can coordinate a particular application, just ask! Members of either team will be happy to direct you to the right place:
- Philanthropy can be reached at (312) 563-7564 or by contacting david_vomholt@rush.edu
- Sponsored Programs Administration, ORA can be reached at ora_grants@rush.edu
Archived philanthropic RFPs from the past year can be found here.
Funding Source | Grant Name | Description | Deadline |
|---|---|---|---|
| Acumed LLC | Education grants | Professional Medical Education Grants: Professional Medical Education Grants provide funding for independent medical educational programs for health care professionals, including congresses, conferences, symposiums, or courses, with or without labs, that are sponsored by professional medical associations, societies, or continuing education providers and academic institution labs. This includes support requested for cadaveric labs intended to educate fellows or residents at an academic institution. More Information | Rolling deadline: Completed application, including all required supporting documentation, must be received at least 60 days before the scheduled date of the event, activity, or program |
| Cancer Research Institute | Irvington Postdoctoral Fellowship Award | The CRI Irvington Postdoctoral Fellowship Program supports qualified young scientists at leading universities and research centers around the world who wish to receive training in fundamental immunology or cancer immunology. A panel of scientists drawn from our Scientific Advisory Council rigorously evaluates each candidate, the intended sponsor and training environment, and the nature and feasibility of the proposed project. The Cancer Research Institute recognizes that getting to the next great breakthrough in cancer treatment will require continued investment in fundamental research and training. CRI, therefore, invites postdoctoral fellows working in both fundamental immunology and tumor immunology to apply for funding. CRI seeks hypothesis-driven, mechanistic studies in both immunology and tumor immunology. The applicant and sponsor should make every effort to demonstrate the potential of the proposed studies to directly impact our understanding of the immune system’s role in cancer. More information | 09/01/2024 Application Due |
| Kenneth Rainin Foundation | Innovator Awards | The Kenneth Rainin Foundation believes that early support for innovative ideas can lead to improvements in preventing, predicting, diagnosing and treating Inflammatory Bowel Disease (IBD). Our Health grantmaking enables researchers worldwide to test ideas, gather and share data, and collaborate to advance the understanding of IBD. In 2022, we consolidated our Innovator Awards and Synergy Awards into one grant program—the Innovator Awards. Innovator Awards support individual research projects with grants of up to $150,000 and collaborative projects involving multiple investigators with grants of up to $300,000. Grantees who demonstrate significant progress are eligible for up to two years of additional support. | 09/30/2024 LOI Due |
| Pfizer | Increase Awareness & Understanding of Emerging Hemophilia Treatment Options | This $100,000 competitive program seeks to encourage organizations to submit grant applications for independent medical education initiatives that will result in the measurable improvement of the medical and scientific understanding of emerging treatment options for patients with Hemophilia. Project Types and Area of Interest: Potential applicants are encouraged to identify and address the educational needs of healthcare professionals to increase awareness of emerging hemophilia treatment options. More Information | 09/30/2024 Application Due |
| Pfizer | Early Diagnosis Improvement of Chlamydia Infections | This competitive $100,000 program seeks to support health care professionals medical education to improve early diagnosis of chlamydia infections. Applicants are encouraged to develop educational programs to identify and address the educational needs, barriers, and gaps for early diagnosis of chlamydia. Under this RFP, grants will be offered to support evidence-based programs, with a high reach potential, aiming to improve routine screening practices, appropriate diagnostic methods for chlamydia, use of latest guidelines, and best practices for early diagnosis of chlamydia infections. Educational programs with a focus on addressing specific challenges faced by marginalized populations are also within scope. Independent medical educational proposals may include live and/or virtual & theoretical and/or practical activities, educational public health interventions, enduring courses, workshops, modules, handson-training, educational resources and tools, technology platforms and social media, or any combination of traditional and/or innovative formats. More Information | 10/01/2024 Application Due |
| Pfizer | Closing the Gaps within Intestinal Ultrasound | The IBUS-Pfizer GMG collaboration invites proposals for research projects that address the following priority areas within the field of intestinal ultrasound (IUS) in inflammatory bowel disease (IBD): 1. IUS in Monitoring IBD: Proposals should focus on the broader role of IUS in monitoring various aspects of IBD, including disease activity, treatment response (including, but not limited to, Etrasimod), and complications. The primary outcome should be IUS-based findings, and the study design should allow for a multi-center approach. 2. Perianal IUS in Proctitis: Proposals should investigate the impact of perianal IUS on monitoring proctitis across various treatment modalities (including but not limited to Etrasimod). Multi-center studies are encouraged to provide a comprehensive understanding of this under-researched area. 3. IUS in Special Populations: Proposals should explore the utility of IUS in monitoring ulcerative colitis and Crohn's disease in pregnant women, adolescents, and children. This area represents a significant gap in our knowledge and has the potential to improve care for these specific patient populations. 4. IUS Education: Proposals should investigate strategies for enhancing IUS competency development among healthcare professionals. This may include research on curriculum development (perianal, pediatric, advanced IUS, train-the-trainer), standardization of techniques (contrast-enhanced ultrasound, elastography), and evaluation of different learning modalities. 5. IUS in monitoring treatment with Etrasimod in a real-world setting: The use of IUS in monitoring the effectiveness of Etrasimod in UC. We encourage proposals that utilize quantitative, qualitative, or mixed-methods approaches and involve primary data collection, secondary data analysis, or a combination of both. While formal cost-benefit or cost-effectiveness analyses are not required, proposals should demonstrate the potential value and impact of the proposed research for improving patient care and advancing the field of IUS in IBD. More Information | 10/01/2024 Application Due |
| Whitehall Foundation | Research Grants | Research grants are available to established scientists of all ages working at accredited institutions in the United States. Applications will be judged on the scientific merit and the innovative aspects of the proposal as well as on the competence of the applicant. Research grants of up to three years will be provided. A renewal grant with a maximum of two years is possible, but it will be awarded on a competitive basis. Research grants will not be awarded to investigators who have already received, or expect to receive, substantial support from other sources, even if it is for an unrelated purpose. The maximum budget is $100,000 per year for the two- and three-year research grants. More Information | 10/01/2024 LOI Due |
| Pfizer | HER2 Expression in Urothelial Carcinoma (UC) | This competitive $10,000-$100,000 grant program intends to create awareness of ongoing clinical trials for UC patients and the scientific data supporting the potential impact of targeting HER2 in locally advanced/metastatic UC. Project Types and Area of Interest Potential: Applicants are encouraged to identify and address the educational needs, barriers and gaps for physicians and all healthcare professionals (HCPs) caring for patients with UC. Under this RFP, grants will be offered to support programs that will strengthen HCP understanding of clinical data in HER2 targeted therapies in UC and awareness of ongoing clinical trials in this area. The goal is to increase patient access to clinical trials and improve equity and diversity in clinical trials. Independent Medical Education proposals may include live and/or virtual activities, enduring courses, resources and tools, technology platforms and social media, or any combination of traditional or innovative formats. More Information | 10/07/2024 Application Due |
| Pfizer | Treating Older Patients with HR+/HER2- Metastatic Breast Cancer (mBC): Best Practices for Their Assessment and Care | General Area of Interest for this RFP: Educational activities that will be considered for Pfizer support will focus on improving the care of older patients with HR+/HER2- mBC to include some or all of the following areas: • Needs of older patients with cancer and how this can inform treatment decisions • Raising awareness of the causes of under- and over-treatment of older adults with cancer with particular focus on the impact on treating HR+/HER2- mBC • Sharing best practices regarding geriatric clinical assessment and specific tools/questionnaires to optimize incorporation of assessment into clinical practice • Exploring provider behaviors when prescribing therapy for older patients with HR+/HER2- mBC that is not guideline-concordant, especially in the community setting • Understanding providers’ unconscious bias regarding perceived frailty in older patients based solely on chronological age • Clinical and social factors that should be considered when prescribing treatment for an older patient with HR+HER2- mBC 2 Examples of educational formats that will be considered under this RFP include but are not limited to: • Opportunities for team-based or multi-disciplinary learning and change strategies • Downloadable tools or clinical practice guides • On-agenda educational sessions during live conferences or stand-alone symposia • Online resources, newsletter articles, training courses, webinars • Social media posted & linked content • Videos, podcasts, infographics, animations It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. More Information | 10/08/2024 Application Due |
| Pfizer | Treating the Whole Patient: Considerations for Patients with HR+/HER2- Metastatic Breast Cancer (mBC) and Existing Comorbiditie | Educational activities that will be considered for Pfizer support will focus on improving the comprehensive care of patients with HR+/HER2- mBC taking into consideration comorbidities and their related factors such as performance status, patient goals, and polypharmacy. Areas of interest include: • Raising awareness of how common comorbidities (i.e. Cardiovascular disease), polypharmacy, and patients with poor performance status/frail patients can be in HR+/HER2- mBC patients • Consideration of the efficacy (RCT)/effectiveness (RWE) and safety of various treatment options and how they align with individualized patient needs and health status in order to support healthcare professionals’ selection of the right treatment for the right patient • Best practices for considerations for drug-drug interactions in the selection of mBC treatment and the monitoring requirements in patients with comorbid conditions. • Incorporation of open and informed discussions between healthcare providers and patients around patient goals and quality of life to support clinical decision-making • Understanding the available Real-World Evidence for the use of CDK4/6 inhibitors, especially in patient subgroups underrepresented in RCTs. More Information | 10/08/2024 Application Due |
| Burroughs Wellcome Fund | Career Awards for Medical Scientists | The Career Awards for Medical Scientists is a highly competitive program that provides $700,000 awards over five years for physician-scientists who are committed to an academic career, to bridge advanced postdoctoral/fellowship training and the early years of faculty service. Proposals must be in the area of basic biomedical, disease-oriented, or translational research. Proposals in health services research or involving large-scale clinical trials are not eligible. More information | 10/08/2024 Application due |
| Pfizer | Addressing Healthcare Disparities in the Outpatient Diagnosis and Management of COVID-19 | Through this competitive $250,000 grant program and RFP process, we aim to support projects addressing healthcare disparities amongst socially disadvantaged or vulnerable populations. This RFP seeks proposals that focus on interventions (e.g., programs, practices, policies) that have potential to reduce or eliminate health disparities. These programs should highlight challenges and social determinants of health (SDOH) associated with receiving a timely diagnosis and receipt of an appropriate COVID-19 treatment amongst eligible patients. 1 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785980 2 Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 ― United States, January–July 2022 | MMWR (cdc.gov) Project Types and Area of Interest Potential applicants are encouraged to identify and address the educational needs, barriers and gaps for equitable healthcare delivery in COVID-19 management among underserved and marginalized populations / communities. This may include: • Educational tools/resources to reduce information barriers and promote knowledge acquisition. • Educational programs to improve knowledge on strategies and effective practices. More Information | 10/08/2024 Application due |
| Pfizer | Optimizing Testing and Treatment in Metastatic Colorectal Cancer (mCRC) | Projects that will be considered for Pfizer support will focus on increasing healthcare professional understanding and competence in the following areas: • Optimize biomarker testing and treatment planning of patients with mCRC in academic and community practice. • Multidisciplinary approach to actioning of early biomarker test results in mCRC. • Improve understanding of validated biomarkers of response in patients with mCRC and consider the implications for molecular testing and incorporation of biomarker results into clinical care. • Increase the medical and scientific understanding of the evolving treatment landscape and emerging lines of therapeutic options in mCRC. • Improve and optimize patient care in terms of both mCRC treatment outcomes and side effect management. More Information | 10/09/2024 Application Due |
| Pfizer | Increase Awareness & Understanding of Emerging Hemophilia Treatment Options | This competitive $100,000 program seeks to encourage organizations to submit grant applications for independent medical education initiatives that will result in the measurable improvement of the medical and scientific understanding of emerging treatment options for patients with Hemophilia. Project Types and Area of Interest Potential applicants are encouraged to identify and address the educational needs of healthcare professionals to increase awareness of emerging hemophilia treatment options, More Information | 10/09/2024 Application Due |
| Pfizer | Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | This $10,000-$20,000 competitive program seeks to encourage organizations to submit grant applications for local level educational activities focused on healthcare professionals involved in the treatment of heart failure patients at risk for TTR Amyloidosis. Project Types and Area of Interest Potential: applicants are encouraged to identify and address the educational needs of healthcare professionals to increase awareness of heart failure patients at risk for TTR Amyloidosis and enable appropriate and early patient identification through an evidence-based approach. More Information | 10/15/2024 Application Due |
| Pfizer | Community Oncology Support for Therapy Management in Multiple Myeloma (MM) | This competitive 2 year $600,000 (total) grant program intends to provide an independent education grant to support to the formation of a new national collaborative initiative which will guide, support, and advise and discuss treatment management of MM patients receiving B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in the community cancer setting. Project Types and Area of Interest: The successful proposal to this RFP will include multiple organizations collaborating together. For example, a collaborative proposal might include some or all of the following: • Academic Cancer Center with experts in BCMA BsAbs • Professional Medical Society with wide reach to community oncologists caring for patients with MM • Medical Education company with strong logistical experience in conducting a national education program • Patient Advocacy Organization to ensure all initiatives reflect the voice and needs of patients. The initiative may include elements such as support for patient initiation and/or transition of care, optimization guidance for treatment management, support for initiation with guidance calls, on-call hours to resolve treatment related questions, and a forum to present cases, best practices and foster the creation of a community of BCMA BsAb treaters. More Information | 10/15/2024 Application Due |
| Conquer Cancer | Career Development Award
| The Career Development Award provides research funding to clinical investigators who have received their initial faculty appointments as they work to establish an independent clinical cancer research program. This research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed. The award is a three-year grant totaling $200,000. More information | 10/17/2024 Application |
| Alpha Phi Foundation | Heart to Heart Grant | As a women’s organization, Alpha Phi Foundation places special emphasis on women’s heart health. In 1993, Alpha Phi Foundation designed an annual grant—the Heart to Heart Grant—to encourage research and education to lessen the impact of heart disease in women. Since its inception, the Heart to Heart Grant has invested over $1.58 million into women’s heart health initiatives. Alpha Phi Foundation announces a single recipient of the $100,000 Heart to Heart Grant every year. More Information | 11/03/2024 Application Due |
| Gerber Foundation | Pediatric Research Grants | Priority is given to projects that improve the nutrition, care and development of infants and young children from the first year before birth to three years of age. The Foundation is particularly interested in fresh approaches to solving common, everyday problems or emerging issues within our defined focus areas: pediatric health; pediatric nutrition, and environmental hazards. Major target areas for research include:
Limit $350,000 on grants with no more than $125,000/year; includes indirect costs. | 11/15/2024 Concept Due |